Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportGeneral Clinical Specialties Track

Potentiation of 177Lu-octreotate PRRT by PARP inhibitors in a 3D spheroid model of human-derived neuroendocrine tumor cell lines

Samuel Adant, Nupur Purohit, Rashmi Shah, Girish Shah and Jean-Mathieu Beauregard
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 243;
Samuel Adant
1Department of Molecular Biology, Medical Biochemistry and Pathology and Cancer Research Center, Université Laval; Neurosciences and Oncology Branches, CHU de Québec – Université Laval Research Center Quebec City QC Canada
2Department of Radiology and Nuclear Medicine and Cancer Research Center, Université Laval; Division of Nuclear Medicine, Department of Medical Imaging, CHU de Québec – Université Laval; Oncology Branch, CHU de Québec – Université Laval Research Center Quebec City QC Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nupur Purohit
1Department of Molecular Biology, Medical Biochemistry and Pathology and Cancer Research Center, Université Laval; Neurosciences and Oncology Branches, CHU de Québec – Université Laval Research Center Quebec City QC Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rashmi Shah
1Department of Molecular Biology, Medical Biochemistry and Pathology and Cancer Research Center, Université Laval; Neurosciences and Oncology Branches, CHU de Québec – Université Laval Research Center Quebec City QC Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Girish Shah
1Department of Molecular Biology, Medical Biochemistry and Pathology and Cancer Research Center, Université Laval; Neurosciences and Oncology Branches, CHU de Québec – Université Laval Research Center Quebec City QC Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Mathieu Beauregard
2Department of Radiology and Nuclear Medicine and Cancer Research Center, Université Laval; Division of Nuclear Medicine, Department of Medical Imaging, CHU de Québec – Université Laval; Oncology Branch, CHU de Québec – Université Laval Research Center Quebec City QC Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Article Information

vol. 58 no. supplement 1 243

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online May 24, 2017.

Copyright & Usage 
© 2017

Author Information

  1. Samuel Adant1,2,
  2. Nupur Purohit1,
  3. Rashmi Shah1,
  4. Girish Shah1 and
  5. Jean-Mathieu Beauregard2
  1. 1Department of Molecular Biology, Medical Biochemistry and Pathology and Cancer Research Center, Université Laval; Neurosciences and Oncology Branches, CHU de Québec – Université Laval Research Center Quebec City QC Canada
  2. 2Department of Radiology and Nuclear Medicine and Cancer Research Center, Université Laval; Division of Nuclear Medicine, Department of Medical Imaging, CHU de Québec – Université Laval; Oncology Branch, CHU de Québec – Université Laval Research Center Quebec City QC Canada

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: May 2017 to April 2025

AbstractFullPdf
May 2017700
Jun 201725800
Jul 20173800
Aug 20172700
Sep 20173700
Oct 20174300
Nov 20173600
Dec 20172100
Jan 20182800
Feb 20183300
Mar 20183400
Apr 20183800
May 20182600
Jun 20181300
Jul 20181400
Aug 20181000
Sep 2018800
Oct 20182700
Nov 20181200
Dec 2018700
Jan 20192200
Feb 2019900
Mar 20191800
Apr 20192500
May 20192700
Jun 20191000
Jul 20191000
Aug 2019800
Sep 20191200
Oct 20191400
Nov 2019900
Dec 20191000
Jan 20201900
Feb 20201000
Mar 20202800
Apr 20201900
May 2020700
Jun 2020800
Jul 2020500
Aug 20202500
Sep 20203200
Oct 20202100
Nov 20202200
Dec 20201100
Jan 20211400
Feb 20211200
Mar 20211100
Apr 20214400
May 20211700
Jun 2021500
Jul 20211900
Aug 20213300
Sep 20212600
Oct 20212600
Nov 20218500
Dec 20216600
Jan 20227100
Feb 20222400
Mar 20222300
Apr 20221900
May 20224300
Jun 20222300
Jul 20222100
Aug 20222100
Sep 20221000
Oct 20221000
Nov 2022800
Dec 20221300
Jan 20232100
Feb 2023900
Mar 20231200
Apr 20231100
May 20231500
Jun 20233100
Jul 20231000
Aug 2023900
Sep 20231000
Oct 20233400
Nov 20232300
Dec 20231500
Jan 20241300
Feb 20241500
Mar 20241300
Apr 20243200
May 20244900
Jun 20241700
Jul 20241100
Aug 20242200
Sep 20241800
Oct 20241400
Nov 20241600
Dec 20241000
Jan 20251100
Feb 20251800
Mar 2025800
Apr 20252200
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 58, Issue supplement 1
May 1, 2017
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Potentiation of 177Lu-octreotate PRRT by PARP inhibitors in a 3D spheroid model of human-derived neuroendocrine tumor cell lines
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Potentiation of 177Lu-octreotate PRRT by PARP inhibitors in a 3D spheroid model of human-derived neuroendocrine tumor cell lines
Samuel Adant, Nupur Purohit, Rashmi Shah, Girish Shah, Jean-Mathieu Beauregard
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 243;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Potentiation of 177Lu-octreotate PRRT by PARP inhibitors in a 3D spheroid model of human-derived neuroendocrine tumor cell lines
Samuel Adant, Nupur Purohit, Rashmi Shah, Girish Shah, Jean-Mathieu Beauregard
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 243;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

General Clinical Specialties Track

  • Quantitative Evaluation of Parathyroid Adenoma and Hyperplasia in Reference to Thyroid using Tc-99m MIBI SPECT/CT
  • Role of 18F-FDG PET/CT in detection of disease burden and response assessment in patients with myeloid sarcoma
  • A primitive study for clinical application of 18F-AlF-NOTA-octreotide PET/CT in combination with 18F-FDG PET/CT for imaging neuroendocrine neoplasms
Show more General Clinical Specialties Track

INTEGRATED SESSION: Neuroendocrine Tumors

  • Clinical feasibility of early scanning after administration of 68Ga-DOTATOC
  • Lesion detection rates of 68Ga-DOTATATE,18F-DOPA and 18F-FDG PET/CT in MEN2A patients - A comparative preliminary study
Show more INTEGRATED SESSION: Neuroendocrine Tumors

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire